?? Regulatory Milestone Achieved! ?? We’re excited to share that ResVita Bio had a productive FDA INTERACT meeting for RVB-003, our investigational therapy for Netherton Syndrome. The FDA's valuable feedback on biocontainment, CMC, and preclinical studies aligns with our innovative continuous protein therapy platform, bringing us closer to our Pre-IND submission in 2025. This milestone reinforces our commitment to transforming the treatment of skin diseases and improving patient outcomes with sustained therapeutic protein delivery directly to the skin. Thank you to our team, partners, and supporters for making this progress possible! ?? #Biotech #SkinDisease #NethertonSyndrome #FDA #Regulatory #Innovation #ContinuousProteinTherapy
ResVita Bio
生物技术
Berkeley，California 1,240 位关注者
Treating skin diseases through engineered skin probiotics
关于我们
The physical and emotional challenges of chronic skin diseases are devastating to patients, particularly children. ResVita Bio seeks to restore and maintain the vitality of the skin through engineered skin probiotics. Through synthetic biology and metabolic engineering, we are developing a safe and versatile skin microbial platform that continuously deliver therapies that address the causes of chronic skin diseases. ResVita Bio is developing a rich product pipeline to treat inflammatory skin diseases like Netherton Syndrome, atopic dermatitis, psoriasis, acne, and rosacea.
- 网站
-
https://www.resvitabio.com
ResVita Bio的外部链接
- 所属行业
- 生物技术
- 规模
- 2-10 人
- 总部
- Berkeley，California
- 类型
- 私人持股
- 创立
- 2021
地点
-
主要
获取路线
2630 Bancroft Way
US，California，Berkeley，94720
ResVita Bio员工
动态
-
?? Exciting News! ?? We're thrilled to announce that the NIH has awarded ResVita Bio a $2.03M Phase II grant to advance RVB-003, our breakthrough treatment for Netherton Syndrome! This is a huge step forward for continuous protein therapy, a revolutionary approach that enables sustained therapeutic protein production directly on the skin—offering unparalleled safety and efficacy for treating skin diseases. This brings us one step closer to transforming the lives of patients suffering from this devastating condition. Stay tuned for more updates as we move closer to clinical development!
National Institutes of Health (NIH) Awards ResVita Bio a $2M Phase II SBIR Grant for Continuous Protein Therapy for Netherton Syndrome
prnewswire.com